We found that several drug targets previously considered promising for SCLC demonstrated lower sensitivity in the high-infiltration group than low-infiltration group, including drugs targeting AURKA, PARP1/2, WEE1, and BCL2 (Fig. 8a). This evidence concerns the gene PARP1 and small cell lung carcinoma.